Somaglutide combined with cilofexo/firsocostat treatment NASH II with positive results

The study reached the main clinical endpoint, and patients with NASH with mild and moderate liver fibrosis were well-resistant to all treatment options.
most common adverse events (AEs) are gastrointestinal reactions.
itching symptoms in patients in the cilofexor group.
all groups had between 5% and 14% of patients who stopped taking drugs because of AEs. After 24 weeks of
treatment, an ex post-mortem analysis of the exploratory therapeutic endpoint of the evaluation of biomarkers of liver health showed a statistically significant improvement in the liver fat degeneration (measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver injury (serum alanine amino transferase (ALT)) indicators compared to the somalutide monotherapy group.
Cilofexo is a nonsteroidal funniol X-subject (FXR) agitant developed jointly by Gilead and Phenex Pharma, and the adaptations currently being developed are as follows: Source: PharmaGo Firsocostat is a acetyl coenzyme A carbidease (ACC) inhibitor developed jointly by Gilead and Nimbus Therapeutics. ACC is the speed limit enzyme in fat synthesis process from the beginning, NASH patients with significantly faster body fat rebirth, so ACC inhibitors can reduce lipid synthesis or accelerate its decomposition.